Results 91 to 100 of about 4,378 (208)
EAPH-09. POTENT CLINICAL AND RADIOLOGICAL RESPONSE TO LAROTRECTINIB IN FIRST CASE OF TRK FUSION HIGH GRADE GLIOMA [PDF]
David S. Ziegler +9 more
openalex +1 more source
HGG-09. FIRST LINE THERAPY OF PEDIATRIC GLIOBLASTOMA WITH LAROTRECTINIB [PDF]
Musa Alharbi +7 more
openalex +1 more source
Activity of larotrectinib in TRK fusion lung cancer [PDF]
Alexander Drilon +10 more
openalex +1 more source
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer
Patients treated with RET protein tyrosine kinase inhibitors (TKIs) selpercatinib or pralsetinib develop RET TKI resistance by secondary RET mutations or alterative oncogenes, of which alterative oncogenes pose a greater challenge for disease management ...
Vivek Subbiah +12 more
doaj +1 more source
The First Case Treated with Larotrectinib of a Novel TMTC2-NTRK3 Fusion Undifferentiated High-Grade Pleomorphic Sarcoma of the Chest [PDF]
Chujie Bai +5 more
openalex +1 more source
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
A. Drilon +37 more
semanticscholar +1 more source
HGG-15. SUCCESSFUL TREATMENT OF AN NTRK-FUSION POSITIVE INFANTILE GLIOBLASTOMA WITH LAROTRECTINIB, A TARGETED TRK INHIBITOR [PDF]
Robin Buerki +6 more
openalex +1 more source
BackgroundOncogenic fusions of neurotrophic receptor tyrosine kinase NTRK1, NTRK2, or NTRK3 genes have been found in different types of solid tumors.
Philippe Metellus +15 more
doaj +1 more source
Background Neurotrophic tropomyosin receptor kinase (NTRK) gene fusions are found in 1% of gliomas across children and adults. TRK inhibitors are promising therapeutic agents for NTRK-fused gliomas because they are tissue agnostic and cross the blood ...
Eric Eunshik Kim +10 more
doaj +1 more source

